Brookfield Business Corp (BBUC)vsNovartis AG ADR (NVS)
BBUC
Brookfield Business Corp
$30.85
-8.21%
INDUSTRIALS · Cap: $6.96B
NVS
Novartis AG ADR
$146.03
+0.44%
HEALTHCARE · Cap: $277.42B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 106% more annual revenue ($56.58B vs $27.46B). NVS leads profitability with a 23.9% profit margin vs -0.1%. NVS earns a higher WallStSmart Score of 51/100 (C-).
BBUC
Hold43
out of 100
Grade: D
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.8%
Fair Value
$324.96
Current Price
$30.85
$294.11 discount
Margin of Safety
-51.8%
Fair Value
$110.12
Current Price
$146.03
$35.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
ROE of 2.4% — below average capital efficiency
Revenue declined 4.5%
Currently unprofitable
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : BBUC
The strongest argument for BBUC centers on Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : BBUC
The primary concerns for BBUC are Return on Equity, Revenue Growth, Profit Margin.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
BBUC profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
BBUC carries more volatility with a beta of 1.38 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 43/100), backed by strong 23.9% margins. BBUC offers better value entry with a 88.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Brookfield Business Corp
INDUSTRIALS · CONGLOMERATES · USA
Brookfield Business Corporation focuses on healthcare, construction and wastewater services in the United States, Europe, Australia, the United Kingdom, Canada and Brazil. The company is headquartered in New York, New York.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other CONGLOMERATES Stocks
Want to dig deeper into these stocks?